PT-141 (10mg Vial) Dosage Protocol
Melanocortin (MC4R) agonist for sexual desire — research/educational dosing reference.
Mix & measure PT-141 · 10 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
Quickstart Highlights
PT-141 (bremelanotide) is a melanocortin receptor agonist that acts on the central nervous system — predominantly through the MC4 receptor — to influence sexual desire and arousal[5][6]. Unlike PDE5 inhibitors that work on blood flow, it engages a brain pathway. Bremelanotide is FDA-approved as Vyleesi, but only for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women[1]; any use for erectile dysfunction or libido in men is off-label / research only. This page outlines an as-needed (PRN) subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks — presented for research and educational use only.
Add 2.0 mL bacteriostatic water to one 10 mg vial → 5 mg/mL (5,000 mcg/mL), a clean dilution for accurate PRN dosing.
1–2 mg taken ~45 minutes before activity. Maximum one dose per 24 hours and limited per week — this is PRN, not a daily course.
At 5 mg/mL, 1 unit = 50 mcg on a U-100 syringe; 1 mg = 20 units (0.20 mL) and 2 mg = 40 units (0.40 mL).
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
Dosing & Reconstitution Guide
A single practical dilution with accurate as-needed dosing, step by step
As-Needed (PRN) Approach (2 mL = 5 mg/mL)
Reconstitute: Add 2.0 mL bacteriostatic water to one 10 mg vial → final concentration 5 mg/mL (5,000 mcg/mL).
Typical dose: 1–2 mg as needed, taken roughly 45 minutes before anticipated activity. This is per-administration, not daily therapy.
Easy measuring: At 5 mg/mL, 1 unit = 50 mcg on a U-100 syringe. So 1 mg reads at 20 units and 2 mg at 40 units — comfortable, easy-to-read volumes.
Limits: Maximum one dose per 24 hours, and keep weekly use limited; exceeding labeled frequency raised the risk of focal skin hyperpigmentation in studies.
Frequency: a single subcutaneous injection as needed, about 45 minutes before anticipated activity. Do not exceed one dose in 24 hours, and keep total use limited per week[1]. The FDA-approved Vyleesi regimen for HSDD in premenopausal women is a single 1.75 mg dose PRN; the figures here are practical research-reference measurements, not approved dosing for any other use.
Reconstitution Steps
Draw 2.0 mL of bacteriostatic water into a sterile syringe.
Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
The 2.0 mL dilution gives a clean 5 mg/mL so each milligram reads at exactly 20 units on a U-100 syringe. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Quantities below assume as-needed (PRN) use over an 8–16 week window, with a 2 mg dose and the limit of one dose per 24 hours.
At 5 mg/mL, one 10 mg vial provides about five 2 mg doses, so plan vials by how often you use it.
- ~16 doses: ~4 vials
- ~24 doses: ~5 vials
- ~32 doses: ~7 vials
- Per dose: 1 syringe
- ~16 doses: 16 syringes
- ~32 doses: 32 syringes
Use ~2.0 mL per 10 mg vial for reconstitution.
- 4 vials: ~8 mL → 1 bottle
- 7 vials: ~14 mL → 2 bottles
One for the vial stopper + one for the injection site per dose.
- Per dose: 2 swabs
- ~32 doses: ~64 swabs → 1 box
Protocol Overview
A concise summary of the as-needed regimen, drawn from labeling and commonly cited reference protocols.
- ▪Goal: Raise sexual desire and reduce related distress; FDA-approved (as Vyleesi) only for HSDD in premenopausal women, shown in two Phase 3 RECONNECT trials[2]. Note the satisfying-sexual-events endpoint was mixed.
- ▪Schedule: Subcutaneous, as needed — one dose ~45 minutes before activity; maximum one dose per 24 hours and limited per week[1].
- ▪Dose Range: 1–2 mg per administration; the approved Vyleesi dose is 1.75 mg PRN.
- ▪Reconstitution: 2.0 mL bacteriostatic water per 10 mg vial gives 5 mg/mL for accurate unit measurements.
- ▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and do not freeze the solution.
Dosing Protocol
A practical as-needed approach with clear limits.
- ▪Start: Try a conservative test dose (1 mg) to gauge tolerability before using a full dose.
- ▪Titrate: Move toward 1.5–2 mg based on response and tolerability.
- ▪Timing: Inject ~45–60 minutes before anticipated activity; individuals may adjust slightly based on personal response.
- ▪Do not exceed: one dose per 24 hours; keep weekly use limited — frequent dosing increased focal hyperpigmentation in studies.
- ▪Site: Subcutaneous in the abdomen or thigh; rotate sites between uses.
Storage Instructions
Correct storage is what preserves the peptide’s stability and activity.
- ▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[9].
- ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) for short-term holding; do not freeze the mixed solution, as freezing can denature peptides[10].
- ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
- ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.
Important Notes
Practical points that keep as-needed administration safe and consistent.
- ▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward[3].
- ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local reactions and maintain absorption[3].
- ▪Cardiovascular caution: Bremelanotide causes transient increases in blood pressure and a small drop in heart rate; the label advises against use in people with uncontrolled hypertension or known cardiovascular disease[1].
- ▪Common side effects: Nausea (most frequent), flushing, headache, and injection-site reactions; nausea is usually worst with the first few doses[1].
- ▪Approval scope: FDA approval (Vyleesi) covers only HSDD in premenopausal women. Use for erectile dysfunction or libido in men is off-label / research and not an approved indication.
How This Works
PT-141 (bremelanotide) is a melanocortin receptor agonist that acts mainly through the MC4 receptor in the central nervous system[5][6]. It engages hypothalamic circuits tied to sexual desire and autonomic arousal — a brain pathway, fundamentally different from PDE5 inhibitors (such as sildenafil) that act on blood flow.
In two Phase 3 RECONNECT trials in premenopausal women with HSDD, PRN 1.75 mg subcutaneous dosing improved validated measures of sexual desire and reduced desire-related distress versus placebo[2]. Honest framing matters here: the co-primary endpoint for satisfying sexual events was mixed, so the benefit is best described as a modest, real effect on desire and distress rather than a dramatic change.
Because MC4R also participates in appetite and energy balance, exploratory work has examined whether melanocortin agonism affects caloric intake and body weight under intensive dosing[7]. That is mechanistic and early-stage — not an approved use.
Important caveat: bremelanotide is FDA-approved — but the approval (Vyleesi) is specifically and only for acquired, generalized HSDD in premenopausal women. Use in men, for erectile dysfunction, or for general libido is off-label and investigational, and is presented here for research and educational purposes only.
Subcutaneous delivery is standard for this molecule and supports practical at-home administration with small injection volumes[8].
Lifestyle Factors
Habits that may support outcomes alongside the protocol.
- ▪Timing & communication: Plan the ~45-minute lead time and align expectations with a partner so use matches anticipated activity.
- ▪Manage nausea: Since nausea is the most common effect, a light meal and unhurried timing can make the first few uses easier.
- ▪Overall well-being: Sleep, stress management and exercise support desire and general sexual health independent of any peptide.
- ▪Blood pressure awareness: Given the transient BP rise, avoid stacking with other agents that raise blood pressure and monitor if you are sensitive.
Potential Benefits & Side Effects
What the clinical evidence describes; effects are modest and individual results vary.
Potential Benefits
- ▪Sexual desire (Phase 3): Improved desire and reduced desire-related distress in premenopausal women with HSDD versus placebo[2].
- ▪Central mechanism: Works on a brain (MC4R) pathway rather than blood flow, so it targets desire/arousal directly[6].
- ▪Honest framing: The benefit is modest — the satisfying-sexual-events endpoint was mixed, so PT-141 is not a guaranteed or dramatic effect[2].
- ▪Off-label note: Reported use for libido/ED in men is not established or approved — that data is anecdotal and investigational.
Common Side Effects
- ▪Nausea, flushing, headache: The most common effects; nausea is frequent and usually worst with the first few doses[1].
- ▪Transient blood-pressure rise: A short-lived increase in blood pressure with a small heart-rate drop; relevant if you have cardiovascular risk[1].
- ▪Focal hyperpigmentation: Darkening of skin/gums can occur, and more frequent dosing than labeled increased this risk[1].
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[3][4].
Pre-Injection Preparation
- ▪Wash your hands well with soap and water.
- ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
- ▪Choose a site (abdomen or thigh) and clean it with a fresh alcohol swab, letting it dry fully[4].
- ▪Draw the intended dose (e.g., 40 units for 2 mg), then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch a skinfold at the chosen site between thumb and forefinger.
- ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[3].
- ▪Skip aspiration for subcutaneous shots — it isn’t needed[3].
- ▪Press the plunger slowly and steadily until it’s fully down.
- ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
- ▪Return the reconstituted vial to the fridge right away.
- ▪Rotate the injection site between uses to prevent irritation.
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides for PT-141 (10 mg).
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
FDA Prescribing Information — Vyleesi (bremelanotide)Official label: PRN 1.75 mg SC for HSDD in premenopausal women, dosing limits (max 1/24 h, 8/month), and precautions including transient blood-pressure increase and focal hyperpigmentation.
- 2
Obstetrics & Gynecology (2019) — RECONNECT trialsTwo Phase 3 randomized trials of bremelanotide 1.75 mg SC PRN for HSDD; improved desire and distress, with a mixed satisfying-sexual-events endpoint.
- 3
CDC — Vaccine Administration / Subcutaneous TechniqueSubcutaneous injection technique: 45–90° insertion, site selection, and no-aspiration guidance.
- 4
MedlinePlus (NIH) — Subcutaneous InjectionsPatient instructions for subcutaneous injections: angle, site rotation, and hygiene.
- 5
Clinical Pharmacology — Bremelanotide ReviewPharmacology of bremelanotide as a melanocortin receptor agonist with central (CNS) action on sexual desire pathways.
- 6
Front. Neuroscience (2019) — MC4R pathwayMelanocortin-4 receptor mechanisms and therapeutic targeting relevant to sexual desire and arousal.
- 7
Diabetes, Obesity & Metabolism (2022) — Spana et al.Phase 1 exploratory work: bremelanotide and MC4R agonism affecting caloric intake and body weight under intensive dosing (not an approved use).
- 8
Usach et al., Advances in Therapy (2019)Subcutaneous injection review: typical and upper-range volumes and pain considerations for at-home delivery.
- 9
Peptide Storage Guide (GenScript)Best practices for storing lyophilized peptides: temperature, humidity, and light protection.
- 10
Cheng et al., AAPS Open (2024)Lyophilized protein drug products; reconstituted-liquid stability commonly assessed at 2–8 °C.
- 11
Prime Lab Peptides — PT-141 (10 mg)PT-141 (10 mg) product page — purity specifications and certificates of analysis.
How to reconstitute PT-141
- 1Wipe the vial stopper and your bacteriostatic-water vial with an alcohol swab.
- 2Draw your chosen amount of bacteriostatic water and inject it slowly down the inner wall of the PT-141 vial.
- 3Let it rest, then gently swirl until fully dissolved — do not shake.
- 4Refrigerate the reconstituted vial and draw each dose with a U-100 insulin syringe.
PT-141 — frequently asked questions
How do I reconstitute a 10 mg vial of PT-141?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to PT-141?
There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store PT-141 after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 10 mg vial of PT-141 provide?
Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is PT-141 approved for human use?
No. PT-141 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.